GC Biopharma’s ALYGLO Signs Contract with Major U.S. PBM

 

GC Biopharma announced on the 2nd that it has signed a contract with a major Pharmacy Benefit Manager (PBM) in the United States to list ‘Alyglo’ in their formulary.

Alyglo is an immune globulin blood product that received approval from the U.S. Food and Drug Administration (FDA) in December of last year. It is a 10% immune globulin solution administered intravenously and is used to treat primary immunodeficiency, also known as congenital immunodeficiency.

A PBM is a company that specializes in managing prescription drugs for private insurance companies in the U.S. Being listed in a PBM formulary means being integrated into the U.S. healthcare insurance system. GC Biopharma plans to follow this contract with additional agreements with 3-5 more PBMs, aiming to cover approximately 80% of U.S. private insurance holders.

Additionally, the company is expediting the launch of Alyglo by signing contracts with prominent specialty pharmacies, a key distribution channel. The first shipment from the Ochang plant is being prepared, and the initial shipment is expected as early as next week. Once the product passes through U.S. warehouses and distributors, actual prescriptions are anticipated to begin by mid-month.

A GC Biopharma representative stated, “We will continue our efforts to enhance patient access to innovative treatments through partnerships with PBMs, specialty pharmacies, and distribution companies in the U.S.”